SCHEMBL584936

SCHEMBL584936

CC(C)=CCC/C(C)=C/COC(=O)c1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.77
ALDH1A1 P00352 1/20 0.59
ALOX15 P16050 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5605086 1.00 TRPV1 (0.77) TRPV1ALDH1A1ALOX15
SCHEMBL584937 1.00 TRPV1 (0.77) TRPV1ALDH1A1ALOX15
SCHEMBL5312466 1.00 TRPV1 (0.77) TRPV1ALDH1A1ALOX15
SCHEMBL3040178 0.99 TRPV1 (0.75) TRPV1ALDH1A1ALOX15
SCHEMBL6445172 0.99 TRPV1 (0.75) TRPV1ALDH1A1ALOX15
SCHEMBL6445166 0.99 TRPV1 (0.75) TRPV1ALDH1A1ALOX15
SCHEMBL11411106 0.99 TRPV1 (0.75) TRPV1ALDH1A1ALOX15
SCHEMBL11411110 0.99 TRPV1 (0.75) TRPV1ALDH1A1ALOX15
SCHEMBL8625199 0.93 TRPV1 (0.72) TRPV1ALDH1A1ALOX15
SCHEMBL8625206 0.93 TRPV1 (0.72) TRPV1ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250212873-A1 VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-07-03 US claimed
US-20250129312-A1 CONSUMER PRODUCT COMPOSITIONS WITH PERFUME ENCAPSULATES PROCTER & GAMBLE (US) 2025-04-24 US claimed
US-12209232-B2 Consumer product compositions with perfume encapsulates THE PROCTER & GAMBLE COMPANY (US) 2025-01-28 US claimed
EP-3689849-B1 PERFUME PRECURSOR TAKASAGO PERFUMERY CO LTD (JP) 2025-01-15 EP claimed
EP-4482306-A1 VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-01-01 EP claimed
EP-4356894-A1 SUSTAINABLE PRODUCT WITH MALODORS Beiersdorf AG (DE) 2024-04-24 EP claimed
US-20230340375-A1 CONSUMER PRODUCT COMPOSITIONS WITH PERFUME ENCAPSULATES PROCTER & GAMBLE (US) 2023-10-26 US claimed
EP-4257663-A1 FOOD CONTACT SURFACE SANITIZING LIQUID The Procter & Gamble Company (US) 2023-10-11 EP claimed
WO-2023192424-A1 VOLATILE HD AC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS CROSS-REFERENCE TO RELATED APPLICATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-10-05 WO claimed
US-11732222-B2 Consumer product compositions with perfume encapsulates THE PROCTER & GAMBLE COMPANY (US) 2023-08-22 US claimed
US-20030036489-A1 Consumable composition comprising perfumed particles and article containing the same THE PROCTER & GAMBLE COMPANY 2003-02-20 US claimed
WO-2002090479-A1 PERFUMED PARTICLES AND ARTICLES CONTAINING THE SAME THE PROCTER & GAMBLE COMPANY (US) 2002-11-14 WO claimed
WO-2002090481-A1 COMPOSITIONS AND ARTICLES FOR EFFECTIVE DEPOSITION OF PERFUME THE PROCTER & GAMBLE COMPANY (US) 2002-11-14 WO claimed
US-20020082244-A1 Compositions and methods for inhibiting bone resorption MERCK & CO., INC. 2002-06-27 US claimed
CN-1302286-A Slow release of fragrant compounds is perfoumery using 2-benzoyl benzoates, 2-alkanoyl benzoates or alpha-keto esters FIRMENICH & CIE (CH) 2001-07-04 CN claimed
EP-1088333-A1 COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION Merck & Co., Inc. (US) 2001-04-04 EP claimed
WO-1999067809-A9 COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION MERCK & CO INC (US) 2001-03-22 WO claimed
EP-1061907-A1 MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2000-12-27 EP claimed
WO-1999067809-A1 COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION MERCK & CO., INC. (US) 1999-12-29 WO claimed
WO-1999045912-A1 MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1999-09-16 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082244-A1 Compositions and methods for inhibiting bone resorption SOST, PTEN, ALPI TRPV1 1672/4885ALDH1A1 4552/4885ALOX15 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.